AKT1 and early-onset autosomal dominant Alzheimer disease: Exos-Cur have great potential in enhancing neuroprotection and attenuating cognitive decline effects in Alzheimer’s disease therapy, as a study on Alzheimer’s disease mice showed that Exos-Cur markedly relieved the symptoms of Alzheimer’s disease by inhibiting phosphorylation of the tau protein via activating the AKT/GSK-3β pathway (Wang et al., 2019).